Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Xspray Pharma in connection with a directed share issue (3)
Mandate

Vinge advises Xspray Pharma in connection with a directed share issue

October 23, 2020 Capital Markets and Public M&A

Vinge has advised the pharmaceutical development company Xspray Pharma in connection with a directed share issue, whereby Xspray receives gross proceeds of approximately SEK 265 million.

The share issue was directed to a number of Swedish and international institutional investors on the basis of an accelerated bookbuilding process. The purpose of the share issue is inter alia to enhance the company’s financial position ahead of negotiating a deal pertaining to its lead product HyNap-Dasa and to continue to expand the company’s product portfolio.

Vinge’s team has consisted of Dain Hård Nevonen, Linnéa Sellström, Joel Magnusson and Linnea Petersson.

Related

Vinge advises the sellers on the sale of Nextory to Bonnier Books

 Vinge has acted as legal adviser to the sellers in connection with Bonnier Books’ acquisition of Nextory, one of Europe’s leading streaming services for audiobooks and e-books. Bonnier Books is acquiring all shares in Nextory, and the transaction comprises Nextory’s operations in Sweden and internationally. The acquisition is a cash transaction and the parties have agreed not to disclose the purchase price. The transaction is subject to customary regulatory approvals.
September 02, 2026

Vinge has advised Nimlas in connection with six strategic acquisitions that strengthen the group's position in the Swedish installation market

 Nimlas, with KLAR Partners as majority owner, is one of the Nordic region's leading installation groups, comprising close to 140 companies and 5,000 employees in Sweden, Finland and Norway.
September 02, 2026

Vinge has advised Aspira Partners on the establishment of Aspira Fund I

 Vinge has advised Aspira Partners ("Aspira") on the establishment and fundraising of Aspira's inaugural blind-pool fund, Aspira Fund I (D) AB and Aspira Fund I (E) AB (collectively, "Fund I" or the "Fund").
August 31, 2026